Cor Vasa 2023, 65(1):57-64 | DOI: 10.33678/cor.2022.109

Matrix metallopeptidase-9 prognostic role in STEMI patients after percutaneous coronary intervention (PCI) in one-year follow-up period

Mykola Kopytsya^a, Yaroslava Нilоva^a, Iulia Rodionova^a, Anton Bilchenko^a, Inna Kutia^a, Borys Shelest^b

^a Government Institution "L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine", Kharkiv, Ukraine

^b Kharkiv National Medical University, Department of Internal and Occupational Diseases, Kharkiv, Ukraine

Objective: The use of matrix metallopeptidase-9 (MMP-9) in patients with acute myocardial infarction with ST-segment elevation (STEMI) after percutaneous coronary intervention (PCI) as a prognostic indicator has a lot of gaps and the medical community has very limited experience with it. The study aimed to evaluate the prognostic role of MMP-9 in STEMI patients after successful revascularization within a 12-month follow-up period. Material and method: 88 patients met the inclusion criteria and had no exclusion criteria diagnosed with STEMI who underwent primary PCI were enrolled in the study. 66 (75.0%) were men, with a mean age of 60.84±9.68 years. A follow-up period was 12 months. The combined endpoint was used and it included the occurrence of heart failure, which required hospitalization, cardiovascular death, recurrent myocardial infarction, acute cerebrovascular event. The level of MMP-9 was determined by ELISA.

Keywords: Matrix metalloproteinase-9, Myocardial infarction, Percutaneous coronary intervention

Received: July 3, 2022; Revised: July 3, 2022; Accepted: October 14, 2022; Published: March 1, 2023  Show citation